Longevity Treatments: A Biological Lottery That Widens Health Inequalities

A new study shows that life-extending treatments vary in effectiveness due to genetics and environment, risking deeper health inequalities. Policymakers must ensure equitable access to prevent a longevity divide.

**1. THE NEWS**

A recent study published by SciTechDaily and supported by Longevity Drugs reveals that life-extending treatments may not work equally for everyone. Individual genetic makeup, environmental factors, and lifestyle habits significantly influence the efficacy of these interventions, turning the quest for longevity into a 'biological lottery.'

**2. WHY IT MATTERS**

This finding is particularly alarming for developing nations and communities with limited access to healthcare. In Turkey, where average life expectancy is 78 years but varies by up to 5 years between urban and rural areas, expensive longevity drugs could exacerbate existing disparities. If only the wealthy can afford these treatments, the gap in life expectancy between socioeconomic groups will widen. Globally, the World Health Organization reports an 18-year life expectancy gap between high- and low-income countries, a divide that could become a chasm.

**3. CONTEXT & EXAMPLES**

Historically, medical breakthroughs have followed a pattern: initially costly and accessible only to the rich, then gradually becoming affordable. For instance, statins and vaccines were once expensive but are now cheap. However, longevity treatments involve personalized approaches like gene therapy, which can cost over $1 million per patient in the US. In contrast, Nordic countries like Sweden integrate such treatments into universal healthcare, ensuring more equitable access. Turkey's healthcare system, though improving, relies heavily on out-of-pocket payments for advanced therapies. Data from the Turkish Statistical Institute shows that the wealthiest 20% live 4 years longer than the poorest 20%. Without policy intervention, longevity treatments could widen this gap further. Additionally, the concept of 'healthspan' versus 'lifespan' is crucial: extending life without quality of life may not be desirable.

**4. FORWARD LOOK**

Policymakers must act now to prevent a longevity divide. Turkey could establish a 'Longevity Commission' within the Ministry of Health to evaluate the cost-effectiveness and ethical implications of these treatments. International cooperation is needed to ensure that research focuses not only on genetic factors but also on social determinants of health. The ultimate goal should be to democratize longevity, making it a right rather than a privilege. The coming decade will test whether societies can manage this biological lottery fairly.